tetano
Editor, Senior Moderator
Sci Rep
. 2025 Nov 11;15(1):39487.
doi: 10.1038/s41598-025-23136-2. Mass production of IgY-containing tablets for COVID-19 transmission control
Michelle Hawkins[SUP] 1 [/SUP], Brian Robley[SUP] 1 [/SUP], Farhang Alem[SUP] 2 [/SUP], Aarthi Narayanan[SUP] 2 [/SUP], Philip Larson[SUP] 1 [/SUP], Jason Hull[SUP] 1 [/SUP], Isabella Hajduk[SUP] 3 [/SUP], Michael Wallach[SUP] 4 [/SUP]
Affiliations
Despite the overall positive outcomes in hospitalization and mortality rates from the COVID-19 vaccines, COVID-19 infections remained prevalent around the world highlighting the need for alternative control strategies. Passive immunization with chicken IgY has long served as a feasible countermeasure, which gained further popularity in the research community during the recent pandemic. Here we demonstrate for the first time the scalability of anti-COVID-19 IgY production for effective distribution and potential use in large populations. Over 70,000 chickens were immunized against the SARS-CoV-2 S1 antigen to produce eggs containing anti-S1 IgY. The resulting egg yolk powder was formulated into commercially acceptable tablets for human consumption. QC and stability testing showed that the purified IgY and tablets maintained activity and stability for over a year. The resulting large batch of IgY tablets demonstrated equal immunoreactivity and virus neutralization potential against all leading COVID-19 variants. Our results demonstrate the feasibility of manufacturing egg yolk powder into edible tablets, and that can now be employed to block viral infectivity and transmission against all major COVID-19 variants affordably and effectively in both developed and developing countries.
Keywords: COVID-19; Chicken IgY; Egg yolk powder; Passive immunization; Tablets.
. 2025 Nov 11;15(1):39487.
doi: 10.1038/s41598-025-23136-2. Mass production of IgY-containing tablets for COVID-19 transmission control
Michelle Hawkins[SUP] 1 [/SUP], Brian Robley[SUP] 1 [/SUP], Farhang Alem[SUP] 2 [/SUP], Aarthi Narayanan[SUP] 2 [/SUP], Philip Larson[SUP] 1 [/SUP], Jason Hull[SUP] 1 [/SUP], Isabella Hajduk[SUP] 3 [/SUP], Michael Wallach[SUP] 4 [/SUP]
Affiliations
- PMID: 41219346
- PMCID: PMC12606287
- DOI: 10.1038/s41598-025-23136-2
Despite the overall positive outcomes in hospitalization and mortality rates from the COVID-19 vaccines, COVID-19 infections remained prevalent around the world highlighting the need for alternative control strategies. Passive immunization with chicken IgY has long served as a feasible countermeasure, which gained further popularity in the research community during the recent pandemic. Here we demonstrate for the first time the scalability of anti-COVID-19 IgY production for effective distribution and potential use in large populations. Over 70,000 chickens were immunized against the SARS-CoV-2 S1 antigen to produce eggs containing anti-S1 IgY. The resulting egg yolk powder was formulated into commercially acceptable tablets for human consumption. QC and stability testing showed that the purified IgY and tablets maintained activity and stability for over a year. The resulting large batch of IgY tablets demonstrated equal immunoreactivity and virus neutralization potential against all leading COVID-19 variants. Our results demonstrate the feasibility of manufacturing egg yolk powder into edible tablets, and that can now be employed to block viral infectivity and transmission against all major COVID-19 variants affordably and effectively in both developed and developing countries.
Keywords: COVID-19; Chicken IgY; Egg yolk powder; Passive immunization; Tablets.